How does a 7.5% dividend yield sound?If you're in the market for some promising dividend-paying stocks, good for you! They can be powerful components in your portfolio, ideally delivering not only regular income but also, over time, appreciating stock prices.Dividends are often underappreciated by investors, especially those of us inclined to chase fast-growing high-flying stocks. But dividend-paying stocks are no slouches. Check out the table below and see if it doesn't surprise you. Dividend-Paying Status ...

Core Insights - The 2025 ESC/EAS Dyslipidemia Guideline Update reaffirms high-dose icosapent ethyl (IPE) as a Class IIA recommended therapy for high-risk or very high-risk patients to reduce cardiovascular events based on the REDUCE-IT trial findings [1][14] Group 1: REDUCE-IT Trial Findings - Three sub-analyses from the REDUCE-IT trial demonstrate significant reductions in cardiovascular disease (CVD) risk and outcomes associated with IPE administration in patients with cardiovascular-kidney-metabolic (CKM) syndrome, stratified by baseline apolipoprotein B (ApoB) and fasting triglyceride-rich lipoprotein cholesterol (TRL-C) levels [1][2] - IPE treatment showed a 44% relative risk reduction (RRR) for the primary composite endpoint in patients with an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m², with a hazard ratio (HR) of 0.56 (95% CI 0.39, 0.79), P = 0.001, and an absolute risk reduction (ARR) of 11.2% [4][5] Group 2: Impact on Major Adverse Cardiovascular Events (MACE) - IPE treatment resulted in significant reductions in MACE across all quartiles of baseline ApoB and TRL-C concentrations, with HRs ranging from 0.72 to 0.80 for ApoB and from 0.74 to 0.68 for TRL-C, all with P ≤ 0.02 [8][9] Group 3: Hospitalization and Mortality Outcomes - IPE significantly reduced total hospitalizations (HR 0.91, 95% CI 0.84, 0.98, P=0.017) and increased the likelihood of surviving without hospitalization (odds ratio (OR) 1.12, 95% CI 1.02, 1.22, P=0.016) [12][13] Group 4: Clinical Recommendations - The ESC/EAS guidelines recommend high-dose IPE for patients with elevated triglyceride levels (135–499 mg/dL) despite statin therapy, emphasizing its role in reducing CVD events [14]

Core Insights - Acoramidis has shown a significant reduction in cardiovascular mortality (CVM) risk by 44% over 42 months post-randomization, establishing a new standard for outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) [1][2] - The treatment also demonstrated a 46% hazard reduction in the composite outcome of CVM or first cardiovascular hospitalization (CVH) over the same period [1] - Acoramidis has been approved by the U.S. FDA as Attruby and by the European Commission, Japanese Pharmaceuticals and Medical Devices Agency, and UK Medicines and Healthcare Products Regulatory Agency as BEYONTTRA [1][5] Efficacy and Clinical Benefits - In the ATTRibute-CM study, acoramidis exhibited the fastest benefit observed in any Phase 3 study for ATTR-CM, with significant improvements noted as early as 3 months [1] - At Month 30, there was a 42% reduction in composite all-cause mortality (ACM) and recurrent CVH events compared to placebo [1] - A 50% reduction in the cumulative frequency of CVH events was also reported at Month 30 relative to placebo [1] - Acoramidis treatment resulted in improved or stable NT-proBNP levels in approximately 50% of participants at Month 30, compared to fewer than 20% in the placebo group, indicating meaningful clinical improvement [3] - The treatment also showed a greater proportion of patients with stable or improved NAC Stage at Month 30 compared to placebo, suggesting better disease stabilization [3] Regulatory and Commercial Developments - BridgeBio Pharma has entered into an exclusive licensing agreement with Bayer Consumer Care AG for the commercialization of BEYONTTRA in Europe [4] - Future medical meetings are planned to present additional data on the benefits of Attruby for ATTR-CM patients [5]

外资巨头大举买入中国资产。 香港交易所最新披露的数据显示，摩根大通、花旗集团、摩根士丹利近日增持了宁德时代、中兴通讯、药 明康德等H股。另据摩根士丹利最新发布的报告，全球对冲基金加大了对中国股票的押注力度，8月有望创 下自2月以来单月买入规模之最。 市场表现方面，港股三大指数8月延续涨势，恒指月累计涨幅为1.23%，月线录得四连阳。展望后市，机 构普遍认为，随着美联储降息预期升温，全球流动性环境趋于改善，港股市场仍具备进一步上行的动力。 外资新动作 8月29日，据香港交易所披露，多家外资机构大举买入中国资产，具体来看： 摩根大通对宁德时代H股的多头持仓比例于8月26日从5.98%增至6.06%；对中兴通讯H股的多头持仓比例 于8月21日从6.27%增至6.98%；对药明康德H股的多头持仓比例于8月21日从5.87%增至6.01%。 对于宁德时代股价大涨，有分析表示，随着新车型发布和销售旺季到来，2025年国内新能源汽车销量有望 保持高增长，带动电池和材料需求，固态电池产业化趋势明确。 国信证券研报指出，锂电行业"反内卷"持续推进，部分细分环节价格自律共识逐步达成，行业竞争格局有 望改善。同时，固态电池产业化进 ...

星标 ★ IPO日报 精彩文章第一时间推送 "蓝色小药丸"万艾可的大名如雷贯耳，但事实上，市面上远不止一款用于治疗男性勃起功能障碍（ED）的药 物，"国产伟哥"早已面世。 近日，拥有第二款"国产伟哥"昂伟达®的苏州旺山旺水生物医药股份有限公司（下称"旺山旺水"）二次递表向 港股市场发起冲击，中信证券是独家保荐人。公司今年1月向港交所递交招股书后失效。 IPO日报注意到，这家手握"新冠特效药"和ED新药的公司， 持续"失血"让其急需上市融资 。 制图：佘诗婕 两款核心产品如何？ 据悉。旺山旺水成立于2013年，是一家综合一体化生物医药公司，从事发现、获取、开发和商业化创新小分子 药物，专注于抗病毒、神经精神及生殖健康三大领域。 在这三个领域，旺山旺水已经拥有了三款知名产品（包括两款核心产品LV232、TPN171及一款关键产品 VV116）。 其中，LV232是一款潜在的同类首创双靶点5-羟色胺转运体（"5-HTT"）╱5-羟色胺3（"5-HT3"）受体调 节剂，目前正准备进行治疗抑郁症的II期临床试验。TPN171是一款潜在同类最佳、高效及高选择性的磷酸二酯 酶5（"PDE5"）抑制剂，已于乌兹别克斯坦及中国 ...

Core Insights - The FDA has approved Wayrilz (rilzabrutinib) as the first BTK inhibitor for adults with persistent or chronic immune thrombocytopenia (ITP) who have not responded adequately to previous treatments [1][11] - The approval is based on the LUNA 3 phase 3 study, which demonstrated significant improvements in platelet counts and other ITP symptoms [1][6] Company Overview - Sanofi is committed to addressing unmet patient needs through innovative therapies, with Wayrilz representing a significant advancement in the treatment of ITP [3][11] - The company utilizes its TAILORED COVALENCY® technology to selectively inhibit BTK, which plays a critical role in immune-mediated disease processes [11] Study Details - The LUNA 3 study involved 202 adult patients and showed that 64% of patients on Wayrilz achieved a platelet count response at 12 weeks compared to 32% in the placebo group [3][10] - Patients on Wayrilz reported a 10.6-point improvement in health-related quality of life measures, while the placebo group showed a 2.3-point increase [4] Treatment Mechanism - Wayrilz functions as a novel oral, reversible BTK inhibitor that targets multiple pathways in the immune system, addressing the root causes of ITP through multi-immune modulation [2][11] - This approach is expected to provide a new treatment option for patients who have not responded to traditional therapies [5][6] Regulatory Status - Wayrilz has received Fast Track and Orphan Drug Designations from the FDA for ITP, and similar designations in Japan and the EU [8] - The drug is also under regulatory review for ITP in the EU and China, indicating potential for broader market access [8] Patient Support - Sanofi offers the HemAssist patient support program to assist patients with treatment navigation, insurance coverage, and financial assistance [9]

Eisai and Biogen received US regulatory approval for a new self-injected form of their Alzheimer’s drug Leqembi, in a move that could make a complicated treatment regimen more convenient for patients taking the drug long term https://t.co/3TkmmUjTiT ...

SAN FRANCISCO, Aug. 29, 2025 (GLOBE NEWSWIRE) -- On August 28, 2025, investors in Telix Pharmaceuticals Limited (NASDAQ: TLX) saw the price of their American Depositary Shares fall about 16% after the company said the FDA sought more data on its drug to detect a form of kidney cancer. The development comes after Telix revealed, on July 22, 2025, that it received a subpoena from the SEC, driving the price of ADSs down 10% the next day. National shareholders rights firm Hagens Berman continues to investigate ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Key Takeaways Axsome stock jumped 20.2% in a month, far outpacing its industry, sector and the S&P 500.Auvelity sales hit $215.9M in H1 2025, up 82.3% year over year, driving the company's top-line.Sunosi adds to AXSM's revenue momentum while new migraine drug Symbravo is likely to diversify the portfolio.Axsome Therapeutics (AXSM) delivered a strong performance over the past month, with its shares rallying 20.2% compared with the industry’s rise of 2.5%. The stock has also outperformed the sector and the S ...